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ABSTRACT 
 
 
 For many years it has been known that the injection of antigen bound to an antibody leads 
to more than a 1000-fold increase in antigen specific antibody response.  This observation holds 
true for IgE, which is dependent upon CD23 expression, as this enhancement is not present in 
mice deficient in CD23.  It also has been shown that when mice are injected with IgE-antigen 
complexes also display an increase in antigen specific T cell proliferation. 
While there are published studies that demonstrate a role for B cell derived exosomes in 
the activation and proliferation of T cells, none have focused upon the potential role of CD23 as 
a molecular basis for this phenomenon, at least in the context of allergy and asthma.  This thesis 
provides direct evidence that B cell-derived exosomes possess co-stimulatory molecules, 
including CD80 and CD86, which act in concert with CD23 to induce T cell proliferation, at 
least in vitro.   This is due to, or enhanced by, the exosomal transfer of the antigen or peptide to 
T cells.  Importantly, the antigen transfer is dependent upon the availability of IgE and the 
expression of CD23. 
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I. IgE and Allergy 
 
 Type I hypersensitivity (allergy) is caused by the development and release of antibodies 
by activated B cells against what normally would be considered harmless proteins (allergens).   
Although most allergens are proteins, some are lipids, carbohydrates or proteases (e.g., the dust 
mite allergen, Der p1).
1
  Type I allergy reactions have emerged as one of the most common 
chronic diseases in the industrialized world, and is present across all age, sex, and ethnic groups.
2
  
Allergen exposure and sensitization elicits a TH2-cell response in which Interleukin 4 (IL-4) and 
IL-13 drive an Immunoglobulin E (IgE) response due to class switch recombination in B cells.
3
  
IgE, which is thought to have evolved as the immune system’s main defense against helminths 
and parasitic pathogens, is the key mediator of allergic disease.
4
  The symptoms of Type I 
hypersensitivity arise when an allergen molecule binds to two IgE antibodies, which are bound to 
the high-affinity receptor for IgE, FcεRI, on the surface of mast cells or basophils.5  (See Figure 
1)  Cross-linking of adjacent IgE molecules by allergens exacerbates the allergic response, 
causing the release of biologically active products, such as histamine, lipid mediators, and newly 
produced cytokines leading to inflammatory reactions.
6
 
 IgE, as is true for other classes of antibodies, contains two identical heavy chains and two 
identical light chains.  Whereas IgG contains two heavy chain domains in its Fc region, IgE 
contains three domains.  (See Figure 2)  Structurally, IgE is asymmetrically bent in the Fc region, 
with one Cε3 domain “open” and the other “closed” against the adjacent Cε2 domain.7  This 
structural asymmetry is a key feature of IgE’s interaction with FcεRI.8  FcεRI is expressed on a 
variety of cells including: (1) on mast cells and basophils as a αβγ2 tetramer; and (2) as an αγ2 
trimer on human (not murine) antigen presenting cells, monocytes, eosinophils, platelets, and 
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smooth muscle cells.
9
  (See Figure 3)  IgE binding occurs on the extracellular domains of the 
alpha chain and signaling occurs via the immunoreceptor tyrosine-based activation motifs 
(ITAMs) located on the beta and gamma chains resident in the cytoplasm. 
 IgE also acts through FcεRII (known as CD23, the “low affinity” receptor)10.  CD23 is 
distinguished from most other immunoglobulin receptors in that it belongs to the calcium-
dependent (C-type) lectin family.
11
  Interestingly, the name “low affinity receptor” is misleading; 
while the single head affinity for IgE is low, the naturally-occurring trimer exhibits affinity for 
IgE in the range of FcεRI.  In the membrane bound form, CD23 is a trimer with three lectin 
domain “heads” tethered above the outer cell membrane by a triple α-helical coiled-coil stalk.  
(See Figure 4).  IgE binding occurs in the head region of CD23.  Proteolysis of the stalk region 
leads to the release of various forms of soluble CD23 (sCD23) whose biological activities 
depend on their oligomeric state.
12
  Membrane-bound CD23 principally is cleaved by a 
distintegrin and metalloproteinase 10 (ADAM10) to form sCD23.
13
  CD23 exists in two forms, 
which differ in the N-terminal intracellular amino acid sequence – CD23a (first seven amino 
acids) and CD23b (first six amino acids).  CD23a is expressed by activated B cells prior to 
differentiating into plasma cells; CD23b is expressed on inflammatory cells, epithelial cells, and 
B cells when exposed to IL-4.  Unlike other lectins, CD23 does not depend upon carbohydrates 
to bind IgE;
14
  calcium ions (Ca
2+
), however, are required for IgE binding to CD23.
15,16
  While 
the crystal structure of CD23 is not completely known, it does appear that a CD23 trimer can 
bind three molecules of IgE, suggesting an expansive array of cross-linking on the cell 
membrane.
17
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Figure 1 
 
 
  
IgE Binds Allergens 
A. Depiction of the binding of an allergen dimer (gray) by two IgE molecules bound to the 
FcεRI receptors on the surface of a mast cell.  
B,  The complex structure containing a β-lactoglobulin dimer in a complex with two Fab 
fragments. 
Niemi, M., Jylhä, S., Laukkanen , M.L.,  Söderlund, H., Mäkinen-Kiljunen, S., Kallio, J.M., 
Hakulinen, N., Haahtela, T., Takkinen, K., Rouvinen, J., Molecular interactions between a 
recombinant IgE antibody and the beta-lactoglobulin allergen, Structure, 15(11):1413-21 (2007). 
  
Mast cell 
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Figure 2 
 
 
 
 
Structure of IgE and IgG 
 
IgE shares the same basic molecular structure as antibodies of other classes, with two 
identical heavy chains and two identical light chains.  The heavy ε‑chain contains one more 
domain than the heavy γ‑chain of IgG.  The pair of Cε3 and Cε4 domains are homologous in 
sequence, and similar in quaternary structure, to the pair of Cγ2 and Cγ3 domains of IgG.  The 
pair of Cε2 domains is the distinguishing feature of IgE. 
 
Gould, H. and Sutton, B.J. IgE in allergy and asthma today. Nature Review Immunology. 8, 205-
217 (2008). 
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Figure 3 
 
 
 
 
 
Structure of FcεRI 
The structure of the extracellular domains of the FcεRI α‑chain taken from the crystal structure 
of the FcεRI α‑chain complex.  Also, a representation of the entire IgE molecule bound to the 
extracellular domains of the FcεRI α‑chain, with a depiction of the immunoreceptor tyrosine-
based activation motifs (ITAMs). 
Gould, H. and Sutton, B.J. IgE in allergy and asthma today. Nature Review Immunology. 8, 205-
217 (2008). 
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Figure 4 
 
 
 
 
Structure of FcεRII (CD23) 
An illustration of membrane-bound CD23, showing the extracellular trimeric α‑helical coiled-
coil stalk region, three C‑type lectin domain heads and the C‑terminal tails. Also indicated are 
the glycosylation sites near the base of the stalk. 
 
 
Gould, H. and Sutton, B.J. IgE in allergy and asthma today. Nature Review Immunology. 8, 205-
217 (2008). 
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 CD23 provides several regulatory functions which impact the effects of high levels of 
IgE in allergic disease.  IL-4 and IL-13 induce class switch recombination for IgE synthesis and 
also induce B cells and inflammatory cells to up regulate expression of CD23.  As IgE levels 
increase, CD23 binds to free IgE molecules, thereby acting as a buffer by blocking antibody 
access to available FcεRI receptors.  Additionally, it is believed that CD23 can stimulate and 
repress IgE expression through positive and negative feedback loops.
18
  In humans, but not mice, 
one hypothesis proposes the existence of a positive feedback loop in which ADAM10 cleaves 
membrane bound CD23, allowing sCD23 to co-ligate membrane IgE and CD21
fn1
.
19
  These three 
molecules then form an extensive array and act to induce B cell proliferation and differentiation 
into IgE-producing plasma cells.  IgE is believed to be down regulated (negative feedback loop) 
when cleavage of membrane bound CD23 is blocked so that sCD23 is prevented from forming 
the CD21/membrane IgE signaling platform.
20
  The existence of a positive feedback loop 
provides a therapeutic target: if proteolysis of CD23 can be blocked, IgE levels can be kept at 
levels that do not cause allergic disease.  (See Figure 5) 
 
 
 
  
                                                          
1
 CD21 is called also B2 and is identical with the complement fragment C3d receptor known as CR2 (complement 
receptor-2). CD21 is the major receptor for C3d fragments on immune complexes.  
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Figure 5 
 
 
 
Positive and negative regulation of IgE synthesis by human CD23.   In this model, positive 
regulation of IgE synthesis is a result of the co-ligation of membrane IgE and CD21 on a human 
B cell committed to IgE synthesis by soluble CD23 released from membrane-bound CD23.  The 
negative signaling pathway of CD23 is unknown. 
 
 
 
 
 
 
 
Gould, H. and Sutton, B.J. IgE in allergy and asthma today. Nature Review Immunology. 8, 205-
217 (2008). 
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II. Exosomes 
 
 Membrane proteins may be internalized through clathrin-coated pits and delivered to 
early endosomes.  In the early endosomes, internalized molecules are either recycled to the 
plasma membrane or sequestered in internal vesicles.  Multivesicular endosomes, also known as 
multivesicular bodies (MVBs), are intermediates in the degradation of proteins internalized from 
the cell surface or sorted from the trans Golgi network.
21
 MVBs may fuse with lysosomes where 
the contents are degraded through hydrolase enzymatic action.  In a separate pathway, MVBs 
fuse with the plasma membrane and internal vesicles within the MVB are released into the 
extracellular space as exosomes.
22
  (See Figure 6)  Exosomes display the same orientation as the 
plasma membrane, with extracellular domains of proteins on the surface.  
 Exosomes were first reported in the early 1980s by Trams, Lauter, et al., in connection 
with research on phosphoesterhydrolases from C-6 glioma or N-18 neuroblastoma microvesicles, 
who remarked that exfoliated membrane vesicles may serve a physiologic function; the authors 
proposed that the vesicles be referred to as exosomes.
23
  These microvesicles were further 
characterized by two different research groups studying the recycling of the transferrin receptor 
in reticulocytes.
24,25 
(See Figure 7 and Figure 8).  After these reports, exosome research became 
fairly dormant. 
 Renewed interest in microvesicle research was stimulated in 1996 when Raposo reported 
that Epstein–Barr virus -transformed B-lymphocytes secreted exosomes that bore major 
histocompatibility class (MHC) II dimers bound to antigenic peptides, a complex essential for 
the adaptive immune response.
26
  Subsequently, Raposo demonstrated that dendritic cells (the 
immune cells that initiate adaptive immune responses by presenting MHC–peptide complexes to 
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naïve T cells) also secrete exosomes bearing functional MHC–peptide complexes, which could 
promote induction of antitumor immune responses in mice in vivo.  These results provided the 
basis for the hypothesis that exosomes could play an active role in intercellular communication, 
at least in the immune system.
27
 
 Exosomes originate in the late endosomal compartment and constitute a homogenous 
population with a size ranging from as small as 30 nm with an upper range of 120 nm (the limits 
of the range is the subject of dispute).
28
   Exosomes have been isolated from in vitro cultures of 
virtually every cell type (from mammals, birds, fish, parasites and plants),  including intestinal 
epithelial cells, Schwann cells, and tumor cell lines, but also from primary immune system cells 
such as reticulocytes, mast cells, dendritic cells (DCs), platelets, B lymphocytes and T 
lymphocytes.  In addition, exosomes have been purified from several body fluids, including 
serum and plasma, human bronchoalveolar fluid (BALF), urine, milk or colostrum, and  bile.   
 Exosomes can be isolated through several means,
 29
 including multi-step differential 
centrifugation (probably the most commonly utilitized method), density gradient purification, 
immunoaffinity capture, and a proprietary precipitation method called ExoQuick
TM
.
30
   In 
general, to qualify as an exosome, the vesicle must present the following biophysical 
properties:
31
   
  (a) limited by a bilipidic layer; 
  (b) small diameter (30 to 120 nm); 
  (c) a cup-shaped morphology in electron microscopy; and 
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  (d) floatation on a sucrose gradient with their density between 1.10 - 1.21 
mg/mL, depending on the producing cell type.  (See Figure 9) 
The isolation of exosomes can be further validated by the presence of canonical surface markers, 
including HSP 70, CD9, MHC class I, MHC class II, and/or CD63.
32
  (See Figure 10) 
 Although their exact role in is not known, exosomes have been shown to influence many 
biological processes and diseases.  For example, exosomes contain signal proteins, peptides, 
miRNAs, mRNAs, and lipids.  Exosomes are known to act as messengers between cells by 
eliciting cytokines, and by transferring miRNA, proteins, and antigens to other cells.
33
  In fact, 
one particularly interesting study showed that miRNAs are exchanged during cognate immune 
interactions, demonstrating the existence of antigen-driven unidirectional transfer of miRNAs 
from the T cell to the APC, mediated by the delivery of CD63 
+
 exosomes on immune synapse 
formation.
34
   The study further demonstrated that inhibition of exosome production through 
sphingomyelinase-2 impaired the transfer of miRNAs to APCs.  Similarly, it has been 
hypothesized that one cell communicates with other cells by releasing RNA-containing 
exosomes and modulating the target cell’s protein production.35   
 Tumors of the breast, oral cavity, colorectal, brain, ovary, bladder, prostate, and 
melanomas have been reported to release exosomes.
36
  In cancer, exosomes can play a positive 
and negative role.  While exosomes aid in the removal of potentially detrimental or unneeded 
molecules from cells, tumor-derived exosomes can remove therapeutic drugs.  Moreover, cells 
that have been exposed to chemotherapy release drug-containing exosomes, indicating a 
resistance to treatment.
37
  On the other hand, dendritic cells co-cultured with peptide derived 
from a variety of different tumors mediate a reduction in tumor growth in an MHC and CD8+    
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T cell-dependent manner.
38
  Due to this ability to present antigen to immune effector cells, 
dendritic cell exosomes present a possible treatment for cancer. 
III. Exosomes and Allergy 
 Exogenous antigens (inhaled, ingested, or injected) are taken up by antigen-presenting 
cells (APCs) such as phagocytic cells including dendritic cells and macrophages.  In brief, APCs 
capture an antigen by endocytosis, whereby the cell engulfs some of its extracellular fluid and 
any material dissolved or suspended in that boundary.  That portion of the plasma membrane is 
invaginated and forms a membrane-bounded vesicle called an endosome.  The endosome then 
fuses with a lysosome where the antigen is degraded into short peptides, which in turn displayed 
at the surface of the cell within a MHC Class II molecule.
39
 (See Figure 11)  Once the peptides 
are displayed, they may be recognized by the T cell receptors (TCRs) present on CD4
+
 T cells (a 
process known as “priming”).   In turn, the newly conferred antigen-specific T cells recognize 
the antigens presented by B cells and stimulate the B cells through CD40 ligand (anti-CD40) 
interactions with CD40.  The activated B cells then up regulate costimulatory molecules such as 
CD80 and CD86 that are then able to further stimulate T cells to produce cytokines inducing B 
cells to switch isotypes and differentiate to produce antibodies, such as IgE.
40
  (See Figure 12) 
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Figure 6 
 
 
 
Intracellular Pathways of Endosomes 
Intracellular trafficking occurs through carrier and secretory vesicles that contain 
intraluminal components. By contrast, secreted membrane vesicles contain cytoplasmic 
constituents. Secreted membrane vesicles can form at the plasma membrane by direct budding 
into the extracellular space, giving rise to microvesicles and membrane particles. Secreted 
vesicles also can form inside internal compartments from where they are secreted by fusion with 
the plasma membrane. 
Théry,C., Ostrowski, M., and Segura, E., Membrane vesicles as conveyors of immune responses, 
Nature Reviews Immunology, 9, 581-593 (2009)  
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Figure 7 
  
 
 
Images of Exosomal Release by Electron Microscopy 
 
Thin sections of reticulocytes incubated with colloidal gold-transferrin (AuTf) for 5 min at 37"C. 
AuTf is localized to the free surface of the plasma membrane, within coated pits and vesicles (~ 
100 nm o. d.), inside small uncoated vesicles of varying size (<200 nm; generally 100 nm 
diameter), and inside tubular structures (usually 60-80 nm diameter). Some vesicular profiles 
may represent cross sections of tubular compartments. The clathrin coat is sometimes difficult to 
discern in thin sections, since the reticulocyte cytoplasm stains so densely that it can mask the 
presence of a densely staining coat on the cytoplasmic surface of membrane structures.  When 
reticulocytes were incubated for 20 min or longer at 37° C, AuTf was also found within MVE. 
 
Harding, Heuser, and Stahl.  Receptor-mediated Endocytosis of Transferrin and of the 
Transferrin Receptor in Rat Reticulocytes. The Journal of Cell Biology, 97, 329-339 (1983).  
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Figure 8 
 
 
Close-up of Exosomal Release 
Fusion of multi vesicular bodies (MVB) with the plasma membrane and release of round bodies.  
The small dense bodies are labeled with gold and is only present on the 50-nm bodies which are 
inside vesicles of 300-800 nm in diameter. The limiting membrane of the MVB does not contain 
the gold label. 
 
Johnstone, R., Electron Microscopic Evidence for Externalization of the Transferrin Receptor in 
Vesicular Form in Sheep Reticulocytes, The Journal of Cell Biology, 101, 942-948 (1985). 
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Figure 9 
 
 
 
 
 
 
Characteristics of Secreted Vesicles 
Secreted vesicles represent a heterogeneous class and are separated into types of vesicles 
based upon size and composition. 
 
 
 
Théry,C., Ostrowski, M., and Segura, E., Membrane vesicles as conveyors of immune responses, 
Nature Reviews Immunology, 9, 581-593 (2009) 
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Figure 10 
 
 
 
 
Exosomal Surface Markers 
Proteins found in at least 30% of different exosomes are listed and proteins present in at least 
50% of exosomes are indicated by an asterisk. 
 
 
Théry,C., Ostrowski, M., and Segura, E., Membrane vesicles as conveyors of immune responses, 
Nature Reviews Immunology, 9, 581-593 (2009) 
CD23  
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The activation of T lymphocytes is mediated by the interaction of TCRs with their 
ligands, major histocompatibility molecule-peptide complexes.
41
  The immune synapse, the 
interactions between APCs presenting antigen to T cells, is a critical step in the process of 
eliciting TH2 cell proliferation and maturation, and inducing B cell isotype switching. (See 
Figure 13)  Exosomes from APCs bear MHC class I and II and molecules including CD54, 
CD80, and CD86 known to co-stimulate T cells.  The precise mechanisms underlying exosome-
induced stimulation, however, have not been elucidated.   One line of studies demonstrates that 
exosomes can stimulate T cells directly, whereas others indicate that exosomes must act in 
conjunction with other APCs.
42
  As noted previously, exosomes from APCs (especially dendritic 
cells and B cells) have been shown to carry antigens and antigen complexes.
43
  In one notable 
study, exosomes isolated from B cells were shown to present allergen-derived peptides and to 
induce T-cell proliferation and the production of high levels of IL-4, IL-5, and IL-13 and lower 
levels of IFN-γ and TNF-α, a cytokine profile consistent with an allergen-induced response.44  
Similarly, B cell exosomes loaded with birch pollen peptide also have been shown to induce Bet 
v 1–specific T cell proliferation in a dose dependent manner.45   
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Figure 11 
 
 
 
 
MCH Class II Pathway 
Exogenous proteins taken in by endocytosis are fragmented by proteases in an endosome.  
The alpha and beta chains of MHC class II, along with an invariant chain, are synthesized, 
assembled in the endoplasmic reticulum, and transported through the Golgi and trans-Golgi 
apparatus to reach the endosome, where the invariant chain is digested, and the peptide 
fragments from the exogenous protein are able to associate with the class II MHC molecules, 
which are finally transported to the cell surface.  The exogenous proteins are then displayed for 
antigen presentation to T helper cell. 
http://pathmicro.med.sc.edu/bowers/ant-pres.htm 
 
 
20 
 
Figure 12 
 
 
T Cell and B Cell Interactions and Antibody Production 
 
Antigen-presenting cells prime naive T cells. Antigen-specific T cells recognizing 
antigens presented by B cells in turn stimulate the B cells through CD40/anti-CD40 interactions. 
Activated B cells up regulate costimulatory molecules such as CD80 and CD86 which are then 
able to stimulate T cells. T cell-derived cytokines stimulate B cells to switch isotypes and 
differentiate to produce antibodies. 
 
Wong, F. S., Wen, L., B Cells in Autoimmune Diabetes, Review Diabetic Studies, 2(3):121-135 
(2005). 
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Figure 13 
 
  
 
The Immune Synapse 
The immune synapse, the interactions between APCs presenting antigen to T cells, is a 
critical step in the process of eliciting TH2 cell proliferation and maturation, and inducing B cell 
isotype switching. 
 
Boehm, B. and Bluestone, J. Differential Roles of Costimulatory Signaling Pathways in Type 1 
Diabetes Mellitus, Rev. Diabet. Stud. Winter; 1(4): 156–164 (2004) 
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IV. Experimental Procedures 
 
Reagents 
Rabbit anti-mouse --anti LZ CD23 (diluted 1:250/500), extracellular CD23 held in a 
trimer by the addition of a leucine zipper motif was created as previously described.
46
  Rabbit 
anti-mouse CD9 (Sigma C9993) (diluted1:500/1000).  Mouse anti mouse MHCII H2-I/Adβ 
(5K43) antibody (Santa Cruz sc-71202) (diluted1:500/1000).  Rabbit anti-mouse Mouse IgE, Fc 
specific antibody (Acris AP21485AF-N, diluted 1:500/1000). Rabbit anti-OVA (Abcam 
ab1221), rabbit anti-CD80 antibody (ab64116) and Anti-CD86 antibody (ab112490) were 
purchased from Abcam, Cambridge, Massachusetts.  Goat anti-rabbit HRP was purchased from 
Southern Biotech (Birmingham, Alabama).  Mouse IL-4 was a gift from Bill Paul (National 
Institutes of Health).  
Mice 
BALB/C, DO11.10, OTII and C57BL/6J mice were purchased from Jackson Laboratory 
(Bar Harbor, Maine) and were used in connection with the generation of exosomes, AHR 
experiments, and in the T cell proliferation studies.  Female and male mice ages 8-12 weeks were 
used in the experiments. All mouse protocols were approved by the Virginia Commonwealth 
University Institutional Animal Care and Use committee.  
Cell Culture 
 Cells used in connection with the exosome studies described herein were cultured in 
Complete RPMI, containing 5 mL Penicillin/Streptomycin, 10 mL HEPES, 5mL non-essential 
amino acids, 5 mL sodium pyruvate, 5 mL L-glutamine, 500 µL 2 mercaptoethanol, 50 mL fetal 
bovine serum, 200 µL Gentamycin, and RPMI 1640 added quantum sufficit to 500 mL.  The FBS 
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was centrifuged at 100,000 x g for 2-4 hours to remove possible bovine exosomes prior to 
preparation of the cRPMI. 
 
Isolation of Primary Cells from Mouse Spleens 
After removal, the spleen was gently crushed between sterile microscope slides, the cells 
were placed into 50mL sterile tubes and centrifuged at 1,500 rpm for 5 minutes.  After pouring 
off the supernatant, 10 mL of ACK Lysis Buffer was added to the cell pellet, gently mixed and 
placed on ice.  After 5 minutes the cells were and centrifuged at 1,500 rpm for 5 minutes.  The 
cell pellet was resuspended for cell selection using Miltenyi Biotec MACS Cell Separation 
Microbeads and LS and/or LD columns according to manufacturer’s instructions.  CD45R 
(B220), Order No. 130-049-501, were used to isolate B cells; B cell purity of 98% or greater was 
established by flow cytometry.  For DO11.10 T cell isolation, a cocktail of CD45R, CD11b 
(Order No. 130-049-601) and CD11c (Order No. 130-052-001) Microbeads was prepared and 
added to a single cell suspension of spleen cells.  The labeled cells were passed through either an 
LS or LD column.  The flow through cells were then labeled with L3T4 Microbeads (Order No. 
130-049-201) and passed through an LS column.  The labeled (captured) cells were then used for 
T cell proliferation studies.  DO11.10 T cell purity of 95 % was confirmed by flow cytometry. 
Isolation of Exosomes 
Exosomes were isolated as previously described.   Briefly, primary mouse B cells were 
plated in 6 well plates at a concentration of 1 million cells per milliliter and then cultured for 2 or 
3 days with IL-4 and anti-CD40.   The cells were pelleted by spinning them at 300 x g for 5 
minutes, then 2,000 x g for 10 minutes and supernatants were harvested. To remove any possible 
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apoptotic bodies the supernatants were spun at 27,000 × g (Sorvall RC 5B Superspeed 
Centrifuge, SS34 rotor) for 20 minutes.  The supernatants were passed through a 0.2 μm filter to 
remove particles larger than 200 nm.  Finally exosomes were harvested by spinning at 1 × 
100,000 x g (Sorvall AH-650 or AH-629 rotor) for 1 hour; the exosome pellet was resuspended 
in 5 mL of PBS or HeBS and pelleted again at 100,000 x g for 1 hour. When isolating exosomes 
for CD23 studies, the exosome pellet was resuspended in 100 µL or 200 µL of HeBS with Ca
2+
, 
otherwise the pellet was resupended in PBS.  Electron microscopy was used on some samples to 
confirm that the isolated particles were exosomes.  Bradford Assays or Nanodrop exosome yields 
were approximately 1.0-1.62 µg/µL, depending upon the length of time that B cells were in 
culture.  
Western Blots 
Western Blots were performed using the Life Technologies XCell SureLock Mini-Cell 
Electrophoresis System and 10% Bis-Tris gels for samples.  NuPage MES SDS Running Buffer 
and NuPage MES Transfer Buffer were used according to manufacturer’s instructions.  Briefly, 
20µg of sample per lane was pipetted into the gel and the apparatus ran for 35 minutes at 200V, 
120mA.   Transfer of the samples on to nitrocellulose paper was accomplished using a BioRad 
for 1.5 hours at 100V, 200mA or overnight in a cold room at 25V. 
Blocking was performed either in a 5% powdered milk solution (HeBS or PBS), plus 
0.05% v/v Tween-20  for two hours on an oscillating platform.  Generally, the primary antibody 
was allowed to bind in a cold room overnight. 
For mouse CD23 Western blots, CD23 was detected with rabbit anti-mouse CD23 
followed by goat anti-rabbit HRP antibodies.  For MHC class II blots, the proteins were detected 
using rabbit anti-H2-I/Adβ followed by goat anti-rabbit HRP-conjugated secondary antibodies.  
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Separation of CD23
+
 and CD23
-
 Exosomes 
(a) Bio-Rad Affi-Gel 10 Coupling 
IgE was coupled to Bio-Rad Affi-Gel 10 according to manufacturer’s instructions.  In 
brief, 40 mL of cold isopropanol and then 40 mL of PBS was washed over 5mL of Affi-Gel on a 
Buchner funnel.  Using a spatula, the Affi-Gel was placed into a 15 mL tube.  Next, 10 mg of 
IgE (first dialyzed against PBS) was added to the Affi-Gel.  5 mL PBS was then added to create 
a 50% slurry, to which 100 µL of 1M HEPES was added, to a pH of 7.4.  After breaking up 
clumps with a spatula, the slurry was placed on a nutator in a cold room (4
°
C) overnight.  The 
next day the slurry was washed 5 times in 5 mL PBS by centrifugation at 1,000 rpm, turning off 
machine once 1,000 rpm is reached.  The first three supernatants were kept to assess protein 
content by Bradford Assay.  The Affi-Gel slurry was then treated with 500 µL 2M Tris (pH 8.0-
8.2) + 4.5 mL PBS and placed on a nutator in a cold room (4
°
C) overnight.  The next day the 
slurry was washed by centrifugation 3 times in 5 mL PBS and resuspended in 5mL PBS, plus 10 
mg of NaN3 and stored at 4°C. 
(b) Affi-Gel Exosome Separation  
 To prepare Aff-Gel slurry, stock Affi-Gel was washed two times with 5 mL PBS, spun to 
1,000 rpm and the centrifuge was turned off, then pouring off the supernatant.  The Affi-Gel was 
resuspended in 5 mL PBS.  Next, 1 mL of slurry was placed in a 5 mL Falcon tube.  Once again, 
the slurry was spun to 1,000 rpm and the centrifuge was turned off, and the supernatant was 
poured off.  Approximately 500 µL of Affi-Gel remained in the tube.  The exosome pellet from 
first 100,000 g spin, was resuspended in 1 mL HeBS plus Ca
2+
 and added to the 500 µL IgE Affi 
slurry. The slurry was nutated  in a cold room for 1 hour.  After the slurry was spun to 1,000 
rpm, the supernatant was pipetted, retaining both the supernatant and gel pellet.  To gel 
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supernatant (CD23
-
 fraction), HeBS plus Ca
2+ 
 was added up to a total volume of 5 mL and 
placed in ultracentrifuge tube for second 100,000 g spin.   To recover CD23
+
 exosomes, 4 mL 
HeBS without  Ca
2+
 was added to exosome pellet and 500 µL of 10mM EDTA (1:50 dilution of 
.5M stock) was added to release the CD23
+
 exosomes from the Affi-Gel.  The mixture was 
centrifuged to 1,000 rpm and supernatant was retained.  An additional 500 µL of the EDTA 
solution was added to the pellet, and centrifuged to 1,000 rpm and once again retaining the 
supernatant.  Both supernatants were added to a 5 mL ultracentrifuge tube for second 100,000 g 
spin.  After centrifugation, each pellet was resuspended in 150 µL HeBS plus Ca
2+
. 
T Cell Proliferation Studies 
To determine whether B cell-derived exosomes, with or without added OVA, could 
induce DO11.10 T cell proliferation, 100 μl of exosomes were added to 100,000 T cells per well 
in 100 μl of exosome-free CRPMI and plated in 96 well plates.  After 96 hours of growth, cells 
were pulsed with 1 μ Ci/well of [H3]-thymidine (Perkin Elmer) for 24 hrs. Thymidine 
incorporation was then determined by harvesting the plates using a filtermate cell harvester onto 
GFC plates.  Plates were then dried for approximately two hours. 25 μl of scintillation fluid was 
then added and counts were determined using the TopCount Plate Counter (Perkin Elmer, 
Waltham, Massachusetts). 
Electron Microscopy 
 Exosome samples in PBS were diluted from an initial volume of 150 µL to a total volume 
of 1 mL.  For the negative staining, exosomes were placed on formvar-coated 150-mesh copper 
grids. A drop of the undiluted exosome preparation was placed on a clean parafilm surface.  The 
grid, formvar side to the sample, was then placed on top of the drop of sample and allowed to 
rest for 1 minute. The grid was then picked up and the excess liquid was wicked of with filter 
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paper touched to the edge of the grid.  Next a drop of the stain was placed on the parafilm and 
the grid was put on top of it for 1 minute.  After 1 minute, the grid was picked up, and the excess 
stain was wicked off.  The grid was then allowed to dry completely before scoping. Various 
times were tested, from 30 seconds to 2 minutes and with rinsing after steps, as well as fixation 
with glutaraldehyde.  Final developing solutions were tested:  1% Uranyl acetate, which gave a 
grainy image, and 1% Phosphotungstic acid at pH 7.0, which gave a much smoother stain around 
the exosomes. 
The grids were viewed with the JEOL JEM-1230 Transmission Electron Microscope, 
JEOL USA, Inc., Peabody, MA.  Images were taken with the Gatan UltraScan 4000 CCD 
camera, Gatan, Inc., Pleasanton, California. 
All electron microscopy was performed at the VCU Department of Anatomy and 
Neurobiology Microscopy Facility supported, in part, with funding from NIH-NINDS Center 
core grant (5P30NS047463). 
Airway Hyperresponsiveness or Induced Asthma 
Airway hyperresponsiveness was induced using a mast cell/IgE dependent model, 
previously described by Dr. Stephen Galli.
47
  The mice were sensitized by the intraperitoneal 
injection of 50 μg of OVA in 100 μL of saline on days 1, 3, 5 and 9. Then on day 22 the mice 
were challenged intranasally with (i) exosomes plus 200 μg of OVA in 20 μL of PBS, (ii) 
exosomes carrying OVA peptide (ExoPep), (iii) ExoPep plus 200 μg of OVA, or (iv) 200 μg of 
OVA in 20 μL of PBS and again on day 25 and 28.  After the final OVA challenge (day 29), the 
mice were sacrificed.  Bronchoalveolar lavage fluid (BALF) was collected by lavaging the lungs 
with 1 ml PBS. The BALF was centrifuged and supernatant fluids were saved for further 
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analysis.  Pelleted cells were resuspended in 100 μL PBS, counted, cytospun onto slides and 
stained with Diff-Quik (Siemens Healthcare Diagnostics, Deerfield, Illinois). Percentages were 
determined by counting of at least 200 cells per slide.  
In addition, cardiac puncture was performed to collect serum for total IgE, OVA-specific 
IgE and OVA-specific IgG1 measurements. The heart was then perfused with 10 mL of PBS to 
flush the lungs of blood.  The lungs and heart were removed and fixed in 10% formalin (Fisher) 
and stored at 4°C until paraffin sections could be prepared, if appropriate, by the Anatomic 
pathology research service at VCU.  
Statistical analysis  
All statistics were done using the student’s two-tailed T-test. 
V. Results 
 
  In 2011, Heyman, et al., reported an extensive study of the interrelationship 
among B cells, dendritic cells (CD11c
+
)
 
and T cells.
48
  In the study, CD11c
+
 cells primed in vivo 
with OVA-IgE complexes were able to induce specific T cell proliferation, whereas CD19
+
 B 
cells could not.  While the authors concluded that the data suggested a scenario where 
CD19
+
/CD23
+
 B cells transport IgE-antigen to the spleen where the antigen is captured and 
presented to CD4 T cells by CD11c
+
 cells, they were not able to directly demonstrate the 
delivery of antigen from B cells to CD11c
+
 cells.  The authors noted that antigen could be 
delivered to T cells by several means including pinocytosis, trogocytosis, endocytosis or 
exosomal transfer. 
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Our laboratory previously published a paper indicating that ADAM10 is required for  
CD23 incorporation into exosomes.
49
  My project was to repeat several of these experiments, to 
further characterize exosomes derived from murine B cells, and to determine whether IgE/OVA 
complexes carried by exosomes could provide an effective means of delivering antigen to 
stimulate T cell proliferation. 
A.   B Cell Exosomes Carry Surface CD23 
 
B cells were cultured in exosome free CRPMI under four conditions: (1) 1 µg/mL anti-
CD40 alone; (2) 1 µg/mL anti-CD40 and 10,000 units IL-4; (3) 1 µg/mL anti-CD40 and 50 
µg/mL IgE/DNP; and (4) 1 µg/mL anti-CD40, 10,000 units IL-4, and 50 µg/mL IgE(conjugated 
to either DNP or TNP).  As shown on Figure 14, B cells stimulated with IL-4- express CD23 at 
higher levels than cells not having such stimulation. 
B.   CD23 Positive B Cells May Possess the Ability to Transport IgE 
 
To assess observe the ability of CD23
+
 exosomes to act as APCs to T cells, several 
studies were conducted to determine whether the exosomes could bind IgE and IgE/OVA 
complexes.  The isolated exosomes were passed through SDS Page 10% Bis-Tris gels and then 
transferred to nitrocellulose paper.  The sample was incubated with and without IgE-DNP  in the 
lanes indicated with Acris anti-IgE antibody as the primary antibody and goat anti-rabbit HRP as 
the secondary antibody.  As shown on Figure 15 and Figure 16, there are several bands 
indicating not only the presence of IgE, but several fragments with smaller bands as IgE displays 
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fragments of lesser size.
50
  This would appear to indicate that it is possible for CD23 molecules 
on the surface of exosomes to bind and transport IgE molecules.  
C.   Anti-CD40-Stimulated B Cells Release Greater Amounts of CD23 Positive 
Exosomes Than LPS-Stimulated Cells 
 
LPS is one of the best studied immunostimulatory components of bacteria and, with 
excessive signaling, can induce systemic inflammation and sepsis.
51
  LPS is an important 
structural component of the outer membrane of Gram-negative bacteria.  Stimulation of B cells 
by LPS through the toll-like receptor (TLR) 4 pathway induces B-cell proliferation, antibody 
secretion, and promotes B cells to function as antigen-presenting cells by enhancing expression 
of MHC class II and co-stimulatory molecules.
52
 B cells, therefore, are an important bridge 
between the innate and the adaptive immune system, due to their ability to be activated by 
pathogen-associated molecules like LPS and to generate antigen-specific antibodies.  Another 
study, Figure 17, indicated that murine B cells co-incubated with CD-40L stimulated CD23
+ 
 
exosome release at an amount greater than LPS-stimulated cells.  This result probably is caused 
by anti-CD40 directly stimulates all B cells, whereas LPS utilizes the TLR4 pathway and 
stimulates less than 50% of all B cells.   
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Figure 14 
    
   
 
 
 
B cells stimulated with 
Lane 1-anti-CD40 
Lane 2-anti-CD40+IL-4 
Lane 3-anti-CD40+IgE 
Lane 4-anti-CD40+IL-4+IgE 
Detection of CD23 on Murine B cell exosomes 
B cells were cultured in exosome free CRPMI under four conditions: (1) 1 µg/mL anti-
CD40 alone; (2) 1 µg/mL anti-CD40 and 10,000 units IL-4; (3) 1 µg/mL anti-CD40 and 50 
µg/mL IgE/DNP; and (4) 1 µg/mL anti-CD40, 10,000 units IL-4, and 50 µg/mL IgE(conjugated 
to either DNP or TNP).  Exosomes were then isolated after several centrifugation steps. 
Western Blots were performed 10% Bis-Tris gels for samples.  20µg of sample per lane 
was pipetted into the gel and the apparatus ran for 35 minutes at 200V, 120mA.   Transfer of the 
samples on to nitrocellulose paper was accomplished using a BioRad for 1.5 hours at 100V, 
200mA or overnight in a cold room at 25V.  For CD23 Western blots, CD23 was detected with 
rabbit anti-mouse CD23 (anti- LZ) followed by goat anti-rabbit HRP antibodies.  For MHC class 
II blots, the proteins were detected using rabbit anti-H2-I/Adβ followed by goat anti-rabbit HRP-
conjugated secondary antibodies.  
 
  
Western Blot for CD 23 on murine B cell 
exosomes.  Note cleavage product with IL- 4 
treatment.  IgE stabilizes CD23 on the 
surface. 
50 KDa ----------------- 
27 KDa ----------------- 
Western Blot for MHC Class II to 
confirm successful isolation of 
exosomes 
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Figure 15 
 
 
 
  
 
 
 
Lane 1 WT Balb/c B cells + IL4 + anti-CD40 
Lane 2 WT Balb/c B cells + IL4 + anti-CD40 + IgE-DNP 
Lane 3 WT Balb/c B cells + IL4 + anti-CD40 + IgE-DNP + OVA-DNP 
Lane 4 CD23 K/O+ IL4 + anti-CD40 
Lane 5 CD23 K/O+ IL4 + anti-CD40+ IgE-DNP 
Lane 6 CD23 K/O+ IL4 + anti-CD40+ IgE-DNP + OVA-DNP 
 
Western Blot of exosomes with IgE bound 
 The isolated exosomes were passed through SDS Page 10% Bis-Tris gels and then 
transferred to nitrocellulose paper.  The sample was incubated with IgE-DNP  in the lanes 
indicated,  with Acris AP21485AF-N, (diluted 1:500/1000) as the primary antibody against IgE 
and Goat anti-rabbit HRP as the secondary antibody.   
 
Red box indicates the heavy chain of IgE, whereas the blue box notes the absence of IgE. 
There is some cross-reactivity between the Acris antibody and Ova (44kDa band, in lanes 3 and 
6). 
 
  
50 kDa 
  1      2    3          4       5     6 
100kDa- 
150kDa- 
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Figure 16 
 
 
   
  
 
Lane 1 WT Balb/c B cells + IL4 + anti-CD40 
Lane 2 WT Balb/c B cells + IL4 + anti-CD40 + IgE-DNP +  OVA-DNP 
Lane 3 WT Balb/c B cells + IL4 + anti-CD40 + IgE-DNP  
Lane 4 WT Balb/c B cells + IL4 + anti-CD40 +  OVA-DNP 
 
IgE and CD23 on B cell exosomes 
 
Simultaneous antibody incubation for CD23 and IgE. 
 
 
 
  
1     2      3      4      
50 kD 
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Figure 17 
 
 
 
 
Lane 1 ADAM10
-/-
 stimulated with anti-CD40, IgE-TNP and IL-4 
Lane 2 ADAM10
-/-
 stimulated with LPS, IgE-TNP and IL-4 
Lane 3 WT stimulated with anti-CD40, IgE-TNP and IL-4 
Lane 4 WT stimulated with LPS, IgE-TNP and IL-4 
 
5, 000,000 B cells isolated from WT and ADAM10-/-  mice stimulated with anti-CD40 
(1µg/mL) or LPS (1µg/mL), plus IgE-TNP (50 µg/5mL) and IL-4 (10,000 units).  CD23 was 
detected with rabbit anti-mouse CD23 (anti- LZ) followed by goat anti-rabbit HRP antibodies.   
  
1      2        3      4
 4   4      
50 kD ----- 
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Figure 18 
 
 
 
 
 
IgE Synthesis Pathway 
IL-4 and CD40 ligation are two of the primary signals for IgE synthesis.  In addition, anti-CD40, 
present on TH cells provides the necessary signal for B cell activation. 
 
Conrad, D.H., Ford, J.W., Sturgill, J.L., Gibb, D.R. CD23: an overlooked regulator of allergic 
disease. Curr. Allergy Asthma Rep. 7(5):331-7 (2007). 
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D. B Cell Exosomes Present CD80 and CD86 on their Surface 
 As noted previously, activated B cells up regulate various costimulatory molecules such 
as CD80 (B7.1) and CD86 (B7.2) that are ligands for CD28 on T cells which induce the T cell to 
produce cytokines that induce B cells to switch isotypes and differentiate to produce antibodies, 
such as IgE.
53
  A Western Blot was performed to determine whether the exosomes being studied 
also present CD80 and CD86, and, if so, whether their expression on the surface of exosomes 
differed.  As shown on Figure 19, CD86 is expressed in greater amounts than CD80. 
E. Exosomes Can Be Separated Into CD23 Positive and CD23
 
Negative Populations 
 Using IgE coupled to Affi-Gel, as previously described, several experiments were 
conducted to determine whether B cell-derived exosomes could be separated into CD23 positive 
and CD23 negative subsets.  Figure 20 is a depiction of the steps taken during the process of 
isolating B cell-derived exosomes and subsequently separating the exosomes into CD23 positive 
and CD23 negative subsets. As shown in Figure 21, such a separation is feasible.  The ability to 
separate exosomes into differing subsets based upon surface receptor expression underscores the 
fact that exosomes are not a homogeneous population. 
F. CD 23 is Expressed in ADAM10 K/O Mice 
 
 Our laboratory previously has shown that ADAM10 binding of CD23 was essential for 
sorting into exosomes.  As shown on Figure 22, exosomes from B cells stimulated with IL-4 and 
anti-CD40 do express CD23, albeit at lower levels than wild type mice.  It is possible that 
another ADAM, such as ADAM17, compensate for the loss of ADAM10 thereby providing for 
CD23 exosomal sorting. 
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Figure 19 
CD80 Expression 
 
 
CD86 Expression 
 
 
Expression of CD80 and CD86 on B cell exosomes 
B cells  B cell exosomes 
B cells  B cell exosomes 
40 kDa ----------------- 
40 KDa ----------------- 
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Figure 20 
    
 
 
 
  
 
Figure 19 
  
6 well plate, each well with 4.5 million B cells in 4.5 mL media.  
Stimulated with 2.5 µL IL-4 and 1 µg αCD40 per 1 mL 
Perform exosome isolation procedure.  Each well 
centrifuged separately.  After first 100,000 g spin: 
Add 50 µg IgEαTNP 
Add 50 µg IgEαTNP 
 
4 of the 5 mL tubes - no treatment 
After second 100,000 g spin: 
3 tubes – untreated B cell 
Exosomes, resuspend 
pellet in 200 µL HeBS + 
Ca2+ 
Resuspend IgEαTNP-treated exosome 
pellet in 4.5 mL HeBS and perform 
third 100,000 g spin to see whether 
IgE remains attached. 
Resuspend IgEαTNP-
treated exosome 
pellet in 200 µL HeBS + 
Ca2+ 
Untreated exosomes from one 
tube –Affi-Gel separation into 
CD23+ and CD 23- 
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Figure 21 
 
  
 
 
Lane 1 WT B cell exosomes 
Lane 2 WT B cell exosomes + IgE-TNP, after second 100,000 x g spin 
Lane 3 WT B cell exosomes+ IgE-TNP, after third 100,000 x g spin 
Lane 4 WT B cell exosomes, from Affi-Gel retained supernatant – CD23 negative, no band 
Lane 5 WT B cell exosomes, from Affi-Gel retained pellet – CD23 positive band 
 
Western Blot of IgE-coupled Affi-Gel separation of murine B cell exosomes 
 In brief, in a 6 well plate, each well with 4.5 million B cells in 4.5 mL media.  Each well 
was stimulated with 20,000 units of IL-4 and 1 µg αCD40 per 1 mL.  Exosomes were isolated 
using the previously described centrifugation procedure.  However, after first 100,000 g spin, 
some samples were given 50 µg IgE-TNP, some samples received no additional treatments , but 
were subjected to the Affi-Gel separation procedure and to determine whether exosomes could 
be divided into CD23+ and CD 23- populations.  Other exosomes were subjected to a third 
100,000 x g spin to see whether IgE-TNP remained attached (data not shown). 
CD23 was detected with rabbit anti-mouse CD23 (anti- LZ) followed by goat anti-rabbit HRP 
antibodies.   
  
50 KDa ----------------- 
1         2     3         4       5 
 
 
40 
 
Figure 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD 23 is Expressed On ADAM10 K/O Mice 
Although ADAM10 is important in the sorting of CD23 into exosomes, e exosomes from B cells 
stimulated with IL-4 and anti-CD40 do express CD23, albeit at lower levels than wild type mice.  
It is possible that another ADAM, such as ADAM17, compensate for the loss of ADAM10 
thereby providing for CD23 exosomal sorting. 
 
50KDa- 
  1     2    3       4    5    6 
B cells incubated with: 
1-WT, anti-CD40 
2-WT, anti-CD40 and IL-4 
3-WT, anti-CD40, IL-4 and IgE 
4-AD10KO, anti-CD40 
5-AD10KO, anti-CD40 and IL-4 
6-AD10KO, anti-CD4-, IL-4 and IgE 
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G. Exosomes Can stimulate T cell proliferation  
 
DO11.10 (Balb/c) and  OT-II T (C57BL/6) transgenic mice express a TCR that is specific 
for OVA 323–339 even though the MHC backgrounds of the mice are different.54  Figure 23 is a 
graph of T cell proliferation at various doses of OVA added to Balb/c mouse B cell culture, 
wherein the IgE
+
/IgE
-
 B cells take up the protein and the B cell exosomes carry the OVA peptide 
for presentation to DO11.10 T cells (specific for an OVA peptide).  Figure 24 is a graph of T cell 
proliferation at various does of OVA added to C57/B6 B cell culture for presentation to OTII T 
cells (specific for OVA, but on a C57/B6 background).  In each case, prior to isolating T cells, 
the splenocytes were treated with B220 beads to remove B cells, CD11b beads to remove 
monocytes, and CD11c beads to remove dendritic cells before treated with L3T4 beads to select 
for T cells.  
As evident from the graphs, Balb/c mouse T cells proliferate at a much greater amount 
than those of C57/B6 mice.  This is consistent with other studies indicating that BALB/c mice 
represent a relatively hyperresponsive strain (TH2 prone) as compared to C57BL/6 mice, which 
are generally considered as low TH2 responders (TH1 prone) as they display low airway 
responsiveness in response to an allergen.
55
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Figure 23 
Balb/c mice -- DO11.10 
 
Student’s T-test */**/*** P<.05, .005, or .0001, respectively. 
T cell proliferation in Balb/c mice 
A graph of T cell proliferation at various doses of OVA added to Balb/c mouse B cell 
culture, wherein the IgE+/IgE- B cells take up the protein and the B cell exosomes carry the 
OVA peptide for presentation to DO11.10 T cells. 
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Figure 24 
C57/B6 mice - OTII 
 
Student’s T-test *** P<.0001 
T cell Proliferation in C57/B6 mice 
A graph of T cell proliferation at various does of OVA added to C57/B6 B cell culture for 
presentation to OTII T cells.   
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 Figure 25 illustrates the influence of dendritic cells on the presentation of OVA peptide 
by exosomes.  On Day 1, B cells were isolated and plated the cells at 1 million per 1 mL media 
(total 5 million B cells in 5 mL media) in a 6 well plate with IgE/OVA complexes (50µg/20µg 
per 5 mL) for a 3 day culture before isolating exosomes.  On Day 2, CD11c
+
 dendritic cells were 
isolated and plated in 6 well plates.  To one-half of the DCs,1µg/mL LPS was added for 
stimulation and maturation of the DCs over 24 hours; the other half were untreated.   Finally, T 
cells (100,000), dendritic cells (50,000) and exosomes (100 µL) per 200 µL well were plated in 
various combinations to separate wells of 96 well plates.  The plates were incubated for 3 days 
before T cell proliferation was measured by the incorporation of tritiated thymidine.  
Surprisingly, the exosomes from B cells incubated with OVA induced greater T cell proliferation 
than the proliferation induced by the addition of stimulated DCs. 
 Figure 26 illustrates the critical importance of IgE on the ability of B cell-derived 
exosomes to carry antigen and thereby induce T cell proliferation.  On Day 1, B cells were 
isolated and plated the cells at 1 million per 1 mL media (total 5 million cells in 5 mL media) in 
a 6 well plate.  One subset, the IgE positive subset, was treated with IgE-TNP (50 µ g total), 1 
µg/mL anti-CD40 and 10,000 units IL4 for 24 hours.   Another subset, the IgE negative subset, 
received only 1 µg/mL antiCD40 and 10,000 units IL4 for 24 hours.  The next day the cells were 
washed and 5 µg IgE-TNP was added to the IgE positive subset.  Fresh IL4 and antiCD40 were 
added to both the IgE positive and IgE negative subsets. After four hours, OVA-TNP was added 
in in the amounts noted for 24 hours before isolating exosomes.  T cells (100,000 in 100 µL) and 
exosomes (100 µL out of the total 1mL filtered volume of exosomes produced by 5 million B 
cells) per 200 µL well were plated in groups of five per dosage of OVA to 96 well plates.  The 
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plates were incubated for 3 days before T cell proliferation was measured by the incorporation of 
tritiated thymidine.  As evident from Figure 27, exosomes incubated with IgE prior to the 
introduction of OVA-TNP effectively induce T cell proliferation, whereas B cell exosomes that 
have not been exposed to IgE do not. 
 As noted previously, there is a distinct population of CD23 positive exosomes that can be 
isolated from B cells.  To further this finding, exosomes were isolated from CD23
-/-
 (CD23 
knockout) mice to determine whether the addition of IgE could compensate for the absence of 
CD23.   As in other experiments 1 million B cells per 1mL (5 million cells total) were cultured 
with anti-CD40 (1µg/mL), IL-4 (10,000 units per 5mL).  One WT and one CD23
-/-
 group 
received 10µg/mL of IgE and after washing the cells 24 hours later those cells received a boost 
of 1µg/mL of IgE.  After a 48 hour incubation, exosomes were isolated.  OVA-TNP was added 
in in the amounts noted (.1 µg to 30 µg) for 24 hours before isolating exosomes.  DO11.10 T 
cells (100,000 in 100 µL) and exosomes (100 µL out of the total 1mL filtered volume of 
exosomes produced by 5 million B cells) per 200 µL well were plated in groups of five per 
dosage of OVA to 96 well plates.  The plates were incubated for 3 days before T cell 
proliferation was measured by the incorporation of tritiated thymidine.   
 As shown on Figure 28, only WT B cell exosomes (CD23 positive) that had received IgE 
induced a marked proliferation of DO11.10 T cells.  Neither WT exosomes without IgE nor 
CD23 KO exosomes treated with IgE could induce T cell proliferation. This result further 
confirms the importance CD23 and IgE working in tandem to produce an immune response. 
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Figure 25 
 
 
T cell Proliferation induced by Exosomes and Dendritic Cells 
 On Day 1, B cells were isolated and plated the cells at 1 million per 1 mL media in a 6 
well plate with IgE/OVA complexes (50µg/20µg per 5 mL) for a 3 day culture before isolating 
exosomes.  On Day 2, CD11c
+
 dendritic cells were isolated and plated in 6 well plates.  To one-
half of the DCs, 1µg/mL LPS was added for stimulation and maturation of the DCs over 24 
hours; the other half were untreated.   Finally, T cells (100,000), dendritic cells (50,000) and 
exosomes (100 µL) per 200 µL well were plated in various combinations to separate wells of 96 
well plates.  The plates were incubated for 3 days before T cell proliferation was measured by the 
incorporation of tritiated thymidine.   
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Figure 26 
 
Student’s T-test */** P<.05 or .005 respectively.  
The Effect of IgE on Exosome-Induced T cell Proliferation 
On Day 1, B cells were isolated and plated the cells at 1 million per 1 mL media (total 5 million 
cells in 5 mL media) in a 6 well plate.  One subset, the IgE positive subset, was treated with IgE-
TNP (50 µ g total), 1 µg/mL anti-CD40 and 10,000 units IL4 for 24 hours.   Another subset, the 
IgE negative subset, received only 1 µg/mL antiCD40 and 10,000 units IL4 for 24 hours.  The 
next day the cells were washed and 5 µg IgE-TNP was added to the IgE positive subset.  Fresh 
IL4 and antiCD40 were added to both the IgE positive and IgE negative subsets. After four 
hours, OVA-TNP was added in in the amounts noted for 24 hours before isolating exosomes.  T 
cells (100,000 in 100 µL) and exosomes (100 µL out of the total 1mL filtered volume of 
exosomes produced by 5 million B cells) per 200 µL well were plated in groups of five per 
dosage of OVA to 96 well plates.  Exosomes incubated with IgE prior to the introduction of 
OVA-TNP effectively induce T cell proliferation, whereas B cell exosomes that have not been 
exposed to IgE do not. 
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Figure 27 
 
 
 
Student’s T-test */**/*** P<.05, .005, or .0001, respectively. 
 
CD23 and IgE Critical for T Cell Proliferation 
WT B cell CD23 positive exosomes treated with IgE induced a marked proliferation of 
DO11.10 T cells.  Neither WT exosomes without IgE nor CD23 KO exosomes treated with IgE 
could induce T cell proliferation. 
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 After showing that B cell-derived exosomes could be separated into separate 
subpopulations of CD23
+
 and CD23
-
 exosomes, an experiment was undertaken to see whether 
the CD23
+
 would induce a greater amount of DO11.10 T cell proliferation that CD23
-
 exosomes.  
In this study B cells were isolated from mouse spleens and incubated with anti-CD40 (1µg/mL) 
and IL-4 (10,000 units) for 3 days.  The exosomes were isolated and separated into CD23
+
 and 
CD23
-
 populations as previously described.  Fifteen minutes prior to the second 100,000 x g 
spin, each of the CD23
+
 and CD23
-
 samples further were treated as follows: (1) exosomes only; 
(2) immune complexes (50 µg IgE-TNP and 20 µg OVA-TNP; (3) 50 µg IgE-TNP; and (4) 20 
µg OVA-TNP.  The exosomes were diluted to 1mL of cRPMI and sterile filtered.  100 µL of 
exosomes were added to 100,000 previously stimulated DO11.10 T cells (in 100 µL of cRPMI).  
The T cells had been stimulated with anti CD3 (2C11) and CD28 overnight per the BioLegend 
Mouse T Cell Activation with anti-CD3ε (clone 145-2C11) Protocol 
(http://www.biolegend.com/support/prot) 
 As shown on Figure 28, CD23
+
 treated with immune complexes or OVA-TNP induced 
greater T cell proliferation than CD23
-
 exosomes.  In fact, only CD23
-
 exosomes treated with 
OVA-TNP induced proliferation, which may be due solely to the OVA-TNP and not to an 
exosomal effect. 
H. Experiment to Determine Whether Exosomes Derived from B Cells Cultured With 
OVA Could Induce Airway Hypersensitivity 
 
 Figure 29 is a depiction of the mast cell dependent model of AHR, with 
modifications noted to illustrate four treatment conditions.  In brief, Balb/c mice were sensitized 
by the i.p. injection of 50 μg of OVA in 100 μL of saline on days 1, 3, 5 and 9. On day 22  the 
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mice were challenged i.n.with (i) exosomes plus 200 μg of OVA in 20 μL of PBS, (ii) exosomes 
carrying OVA peptide (ExoPep), (iii) ExoPep plus 200 μg of OVA, or (iv) 200 μg of OVA in 20 
μL of PBS and again on day 25 and 28.  After the final OVA challenge (day 29), the mice were 
sacrificed.  BALF was collected by lavaging the lungs and then centrifuged.  Pelleted cells were 
resuspended in 100 μL PBS, counted, cytospun onto slides.  Cells were counted by visual 
inspection.  Percentages were determined by counting of at least 200 cells per slide. 
As evident from the cell counts set forth in Figure 30, B cell derived exosomes cultured 
with OVA (ExoPep) alone were not sufficient to induce AHR in Balb/c mice.  OVA-sensitized 
mice or mice receiving OVA in conjunction with exosomes did exhibit AHR, but this result 
probably was due to the addition of OVA and not to the exosomes. 
I. Transmission Electron Microscope Picture of B Cell Exosomes 
 
 After isolating B220 B cell derived exosomes, several samples that had not been 
incubated with immune complexes or with OVA were reserved and used for electron 
microscopy.  Figure 31 is a representative example of the exosomes isolated for the studies 
discussed herein. 
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Figure 28  
 
 
CD23
+
 Exosomes Induce Greater T Cell Proliferation Than CD23
-
 Exosomes  
 
CD23
+
 and CD23
-
 exosome populations were separated and then treated prior to the 
second 100,000 x g spin with: (1) exosomes only; (2) immune complexes (50 µg IgE-TNP and 
20 µg OVA-TNP); (3) 50 µg IgE-TNP; and (4) 20 µg OVA-TNP.  The exosomes were plated 
with DO11.10 T cells and then assessed for proliferation. 
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Figure 29 
 
 
 
 
Mast Cell Dependent Model of Airway Hypersensitivity 
Balb/c mice were sensitized by the i.p. injection of 50 μg of OVA in 100 μL of saline on 
days 1, 3, 5 and 9. On day 22  the mice were challenged i.n.with (i) exosomes plus 200 μg of 
OVA in 20 μL of PBS, (ii) exosomes carrying OVA peptide (ExoPep), (iii) ExoPep plus 200 μg 
of OVA, or (iv) 200 μg of OVA in 20 μL of PBS and again on day 25 and 28.  After the final 
OVA challenge (day 29), the mice were sacrificed and BALF was collected. 
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Figure 30 
 
 
AHR BALF Cell Counts 
 After the final OVA challenge, the mice were sacrificed.  BALF was collected by 
lavaging the lungs and then centrifuged.  Pelleted cells were resuspended in 100 μL PBS, 
counted, cytospun onto slides.  Cells were counted by visual inspection.  Percentages were 
determined by counting of at least 200 cells per slide. 
 
  
Flexivent Cell Analysis 
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Figure 31 
 
 
For the negative staining, exosomes were placed on formvar-coated 150-mesh copper 
grids. The grid, formvar side to the sample, was then placed on top of the drop of sample and 
allowed to rest for 1 minute. Next a drop of the stain was placed on the parafilm and the grid was 
put on top of it for 1 minute.  After 1 minute, the grid was picked up, and the excess stain was 
wicked off.  The grid was then allowed to dry completely before scoping. Final developing 
solutions were tested:  1% Uranyl acetate, which gave a grainy image, and 1% Phosphotungstic 
acid at pH 7.0, which gave a much smoother stain around the exosomes. 
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VI. Conclusions 
 For over 100 years, it has been known that antibody aggregation increases binding to Fc 
receptors and results in the increase in the uptake and processing of antigen.
56
  In this regard, the 
injection of antigen bound to an antibody leads to more than a 1000-fold increase in antigen 
specific antibody response.
57
  Moreover, this observation true for IgE, which is dependent upon 
CD23 expression, as this enhancement is not present in mice deficient in CD23.  It also has been 
shown that when mice are injected with IgE-antigen complexes also display an increase in 
antigen specific T cell proliferation.
58
 
 Prior to this past year, the CD23-mediated enhancement was ascribed to B cell antigen 
processing. However, the finding that B cells were only required to transport the IgE immune 
complexes to the spleen challenged this assumption. The Heyman paper asked whether their 
study, which showed that CD19
+
/CD23
+
 B cells transport IgE-antigen to the spleen where the 
antigen is captured and presented to CD4 T cells by CD11c
+
 cells, could be explained by either 
pinocytosis, trogocytosis, endocytosis or exosomal transfer.  The results presented in this thesis 
would suggest that CD23
+
 exosomes play some role, with or without the participation of CD11c
+
 
cells, in antigen transfer.  There is no indication, however, that exosomes solely are responsible 
for antigen transfer.  B cells could still be at least partially involved in the antigen processing 
activities.  Most likely, many different cells –APCs, T cells and B cells – are involved in 
transferring antigenic information at the immune synapse. 
While there are published studies that demonstrate a role for B cell derived exosomes in 
the activation and proliferation of T cells, none have focused upon the potential role of CD23 as 
a molecular basis for this phenomenon, at least in the context of allergy and asthma.  This thesis 
provides direct evidence that B cell-derived exosomes possess co-stimulatory molecules, 
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including CD80 and CD86, which act in concert with CD23 to induce T cell proliferation, at 
least in vitro.   This is due to, or enhanced by, the exosomal transfer of the antigen or peptide to 
T cells.  As also evidenced by the DO11.10 T cell proliferation studies (Figures 23-28), the 
activation is dependent upon the availability of IgE and the expression of CD23. 
B cell exosomes can be loaded with antigen complexes and could serve as a source of 
recycled antigen for uptake by antigen presenting cells.  However, there is little evidence that 
this is an actual in vivo process.  For example, many in vivo studies of exosome function involve 
in vitro co-incubation (pulsing) of the exosomes with large concentrations of antigen or peptide 
in excess of natural conditions prior to adoptive transfer.  In that connection, our lab has 
performed several adoptive transfer experiments (data not presented) using OVA-peptide loaded 
exosomes and transplanted DO11.10 T cells in an attempt to elicit OVA peptide specific T cell 
proliferation.  Spleens taken from mice were taken and stained for DO11.10, CD4 and CD3ε and 
analyzed by flow cytometry.  There are some indications that peptide-loaded exosomes do elicit 
DO11.10 T cell proliferation in vivo.    
This data is suggestive of peptide-loaded exosome induced T cell activation and 
proliferation, but it is not conclusive.  One possibility is that the adoptive transfer of exosomes 
isolated from only 5 million B cells is not sufficient to cause a physiologically significant 
reaction.  In contrast, the i.v. injection of OVA-IgE immune complexes, which would utilize the 
recipient’s entire B cell repertoire, does induce a definitive T cell proliferative response, but the 
amount injected (20µg OVA/50 µg IgE) is much higher than what would be present in exosomes 
from 5 million B cells.  Another possibility is that the exosomes initially traffic to the spleen, but 
they remain there only momentarily and then are dispersed to other organs or tissue.  
Alternatively, the exosomes, by themselves, may not transfer to the spleen with any efficiency.  
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Future experiments, using dye labeled exosomes would be a way to test both this and as well, 
determined the best methodology to get dendritic cell loading of the exosomes.  As mentioned 
above, I have tried experiments (see Figure 32) where LPS activated DC are first incubated with 
the exosomes and then both DC and remaining exosomes are injected, but no significant 
DO11.10 T cell migration into the spleen was seen (Figure 33).    
Two future experiments to test these questions would be to directly inject the exosomes 
into mouse spleen.  This has been reported to be effective for monoclonal antibody preparation.
59
  
In addition, increasing the exosome production by using cell lines such as M12, a murine B 
lymphoma cell line, would allow us to do a better dose response study.  An early experiment 
indicated that exosomes from IL-4 and anti-CD40 stimulated M12 cells incubated with immune 
complexes produced a greater increase in proliferation of DO11.10 CD4
+ 
T cells in vivo when 
injected into CD23KO animals than OVA alone.  Additional studies would confirm or provide 
additional information on this data. 
The ability of exosomes to stimulate both CD4 and CD8 mediated T-cell responses, as 
well as antitumor responses, is suggestive of an antigen-presenting role.
60
  However, it is unclear 
how much of this function relates to the direct acquisition of antigen carrying exosomes by T 
cells, or the indirect processing of exosomal antigen by host DCs that later transfer the antigen to 
T cells.  My study has significant implications for understanding a potential use for exosomes.  If 
the dosage/delivery problems can be solved, the exosomal method of immunization would have 
potential for both the pathogen and tumor vaccine areas of study.   
Finally, there is currently a considerable amount of interest in the micro-RNA that is 
associated with exosomes.  Another future study could look at the mi-RNA that is bound to the B 
cell exosomes and determine if any of the mi-RNA types would enhance the antigen presentation 
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and processing activities.  This has the potential of greatly enhancing the exosome activity 
making smaller amounts of exosome/antigen needed for immunization. 
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Figure 32 Adoptive Transfer Experiments 
 
 B cells, incubated with IL4 (2,000 units/mL), anti-CD40 (1µg/mL)and IgE (50 µg), and then co-
incubated with LPS-stimulated (1µg/mL)  CD11c
+
 dendritic cells can stimulate the proliferation of 
DO.11.10 T cells in vivo in mice. 
 
Group 1 - B220 exosomes, incubated with IL4, anti-CD40 and IgE 50 µg, then 5 µg boost next day, 4 
hours later added 20 µg OVA and  stimulated CD11c
+ 
cells for 4 hours. 
 
Group 2 – Group 1 exosomes, plus additional injection of 20 µg OVA 
 
Group 3 - B220 exosomes, incubated with IL4 and anti-CD40, but no IgE or OVA added to culture and  
stimulated CD11c
+ 
cells for 4 hours, plus 20 µg VA added just prior to injection. 
 
Group 4 – Group 3, but no OVA injection 
 
Group 5 – injection of IC (50 µg IgE/20 µg OVA) 
 
Day 1 
 
B220 cells + IgE/anti-CD40/IL4 
 
Day 2 
 
Wash cells and add 1 µg IgE boost/anti-CD40/IL4 
 
Day 3 
 
Isolate exosomes at 50 µL concentration 
 
Isolate CD11c
+
 cells and stimulate with LPS (1 µg/mL) overnight 
 
Inject DO11.10 T cells into Groups.  Keep T cell sample as unstained control for Day 7 flow. 
 
Day 4 
 
Wash CD11c
+
 cells twice in fresh media to remove LPS.  Incubate 1,250,000 CD11c
+
 cells with 
exosomes for 5 hours with 20 µg OVA 96 well plate.  Inject into Balb/c mice. 
 
Day 5-6 
 
Wait 
 
Day 7 
 
Harvest spleens and run flow for DO.11.10 cell proliferation. 
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Figure 33 
 
1. Immune Complex Group –D011.10 specific proliferation 
 
 
 
2. All Experimental Groups –D011.10 specific proliferation 
 
 
DO11.10 Proliferation from Experimental Groups discussed in Figure 32 
 
1. Immune Complex Group showed 5.02% DO11.10 T cell specific proliferation in spleen.  
The DO11.10 population is evidenced by CD4
hi
/DO11.10
hi
 markers.  Data taken from BD FACSCanto II 
flow cytometer and analyzed using FlowJo software. 
2. Compilation of each group (n=3).  The experimental groups showed little DO11.10 T cell 
proliferation in the spleen.  This may be because (a) peptide carrying exosomes from 5 million B cells are 
insufficient to induce a meaningful response or (b) exosomes do not traffic to the spleen follicles. 
5.02% 
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